ANX-007 is a monoclonal antibody commercialized by Annexon, with a leading Phase II program in Geographic Atrophy. According to Globaldata, it is involved in 5 clinical trials, of which 3 were completed, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of ANX-007s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ANX-007 is expected to reach an annual total of $9 mn by 2040 globally based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ANX-007 Overview
ANX-007 is under development for the treatment of open-angle glaucoma and geographic atrophy. The therapeutic candidate is administered through intravitreal route. It is developed based on classical complement pathway. The therapeutic candidate acts by targeting C1q.
Annexon Overview
Annexon is a biopharmaceutical company that primarily focuses on the development of therapies for autoimmune, neurodegenerative, and ophthalmic diseases. The company’s mainly focuses on inhibiting C1q, the initiating molecule of the classical complement pathway, to prevent inflammation and tissue damage. Annexon‘s products are intended for use in the healthcare industry, specifically for the treatment of serious autoimmune, neurodegenerative, and ophthalmic diseases. The company operates primarily in the US. Annexon is headquartered in South San Francisco, California, the US.
The operating loss of the company was US$143.7 million in FY2023, compared to an operating loss of US$145.6 million in FY2022. The net loss of the company was US$134.2 million in FY2023, compared to a net loss of US$142 million in FY2022.
For a complete picture of ANX-007s valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.